Autolus Therapeutics (AUTL) Misses Q4 EPS by 9c
Tweet
Share
E-mail
Get Alerts AUTL Hot Sheet
Join SI Premium – FREE
Autolus Therapeutics (NASDAQ: AUTL) reported Q4 EPS of ($0.34), $0.09 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $24.29 million versus the consensus estimate of $24.89 million.
For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- KeyBanc Upgrades Nucor (NUE) to Overweight
- Berenberg Starts Barclays Plc (BARC:LN) (BCS) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
